

# OHF Corporate Alliance



## 2020 SPONSORSHIP LEVELS & BENEFITS

# OHF Corporate Alliance

### OHF CORPORATE ALLIANCE OVERVIEW

The OHF Corporate Alliance is a collection of rare Hyperoxaluria stakeholders committed to facilitating collaboration and an information exchange among patients, patient advocacy organizations, health-related organizations, industry, payers, policy makers and regulatory agencies. The OHF Corporate Alliance provides for a seat at the table for all stakeholders, and inspires an open, cooperative approach in addressing issues facing the Hyperoxaluria community. The mission of the OHF Corporate Alliance is to marry the resources and capabilities of industry and patient communities to improve health and expedite access to effective therapies for all patients with Hyperoxaluria. Membership is open to pharmaceutical and biotech companies, industry, service firms, and academia. Associate membership is available for payers, policy makers, and regulatory agencies.

Your membership in the OHF Corporate Alliance shows leadership and commitment to addressing the issues and challenges facing the OHF community. Your involvement also provides OHF with an extended network of expertise and insights that help ensure we continue to positively impact the patients that we all work to serve.

### OUR MISSION

To blend the resources and capabilities of industry and the Hyperoxaluria community, to improve health and expedite access to effective therapies for all patients with Hyperoxaluria.

### AREA OF FOCUS

The OHF Corporate Alliance will emphasize collaboration. Within this area of focus the Corporate Alliance members will demonstrate their commitment to helping improve the quality of education, care, and the life of patients.

### KEY METRICS OF OUR COLLECTIVE IMPACT

- Communities organized, equipped, and activated to drive progress (via advocacy, participation in research, drug and diagnostic development, policy changes and improved/expanded access to care)
- Industry/Academic/Government and collaborative investment in and development of improved diagnostics, treatments and interventions
- Enhanced awareness, knowledge, and attention to hyperoxaluria in society and among key audiences
- Better and more effective identification, diagnosis, and treatment of Hyperoxaluria to improve patient experiences/outcomes
- Support for caregivers in their effort to live with and overcome hyperoxaluria.

# OHF CORPORATE ALLIANCE 2020 ANNUAL MEMBERSHIP



## 2020 CORPORATE ALLIANCE MEMBERSHIP LEVELS

<b>BIOTECH/PHARMACEUTICAL COMPANIES</b>	
Research & Development (less than 20 employees)	\$5,000
Research & Development (20+ employees)	\$10,000
Clinical	\$15,000
Commercial	\$25,000
<b>OTHER ORGANIZATIONS</b>	
<b>SERVICE FIRMS</b>	
Independent Consultant	\$1,000
Less than 20 employees	\$10,000
20+ employees	\$15,000
<b>SPECIALTY PHARMA/PHARMACY/PBM/LABS/CRO'S</b>	
Less than 20 employees	\$10,000
20 - 100 employees	\$15,000
100+ employees	\$25,000
<b>TRADE ORGANIZATIONS</b>	
	\$10,000

## 2020 CORPORATE ALLIANCE MEMBERSHIP BENEFITS

<b>RECOGNITION:</b> OHF website, all promoted Corporate Alliance materials, public outreach, social media
<b>NETWORKING:</b> Opportunities to network with biotech/pharma companies, health-related alliance members, board and scientific members and OHF leadership
<b>PARTICIPATION:</b> Registration to attend in-person annual Corporate Alliance meeting, with invitations to participate on all quarterly calls. (R & D Level < then 20 employees = 1 member, R & D Level 20 + employees = 2 members, Clinical & Commercial Levels = 3 members)
<b>SUPPORT:</b> Complimentary monthly publication of clinical trial announcements and other corporate announcements through OHF web, newsletters and social media channels